CETIRIZINE HYDROCHLORIDE Drug Patent Profile

When do Cetirizine Hydrochloride patents expire, and what generic alternatives are available?

Cetirizine Hydrochloride is a drug marketed by Actavis Mid Atlantic, Amneal Pharms, Apozeal Pharms, Aurobindo Pharma Ltd, Bajaj, Bionpharma, Chartwell Molecular, Lannett Co Inc, Padagis Us, Pharm Assoc, Ranbaxy Labs Ltd, Taro, Teva Pharms, Wockhardt, Regcon Holdings, Apotex, Catalent, Onesource Specialty, Sun Pharm Inds Inc, Perrigo R And D, Aiping Pharm Inc, Amneal Pharms Ny, Apotex Inc, Cipla Ltd, Contract Pharmacal, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Granules, Heritage Pharma, Marksans Pharma, Mylan, Orbion Pharms, Pld Acquisitions, Sun Pharm Inds Ltd, Torrent Pharms Llc, Unichem, Unique, Ivax Sub Teva Pharms, and Ppi-dac. and is included in fifty NDAs.

The generic ingredient in CETIRIZINE HYDROCHLORIDE is cetirizine hydrochloride; pseudoephedrine hydrochloride. There are thirty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cetirizine Hydrochloride

A generic version of CETIRIZINE HYDROCHLORIDE was approved as cetirizine hydrochloride; pseudoephedrine hydrochloride by IVAX SUB TEVA PHARMS on February 25^th, 2008.

Summary for CETIRIZINE HYDROCHLORIDE

US Patents:	0
Applicants:	39
NDAs:	50
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	4,432
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CETIRIZINE HYDROCHLORIDE
DailyMed Link:	CETIRIZINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Phayao	NA
Pengfei Qiu	NA
Shandong New Time Pharmaceutical Co., LTD	PHASE3

See all CETIRIZINE HYDROCHLORIDE clinical trials

Pharmacology for CETIRIZINE HYDROCHLORIDE

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for CETIRIZINE HYDROCHLORIDE

Anti-Allergic Agents

Histamine H1 Antagonists, Non-Sedating

Anatomical Therapeutic Chemical (ATC) Classes for CETIRIZINE HYDROCHLORIDE

R06AE	Piperazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CETIRIZINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYRTEC	Syrup	cetirizine hydrochloride	5 mg/5 mL	020346	1	2007-03-19
CHILDREN'S ZYRTEC HIVES RELIEF	Chewable Tablets	cetirizine hydrochloride	5 mg and 10 mg	021621		2005-03-25

US Patents and Regulatory Information for CETIRIZINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unichem	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210507-001	Sep 10, 2024		DISCN	No	No
Aurobindo Pharma Ltd	CETIRIZINE HYDROCHLORIDE HIVES RELIEF	cetirizine hydrochloride	TABLET;ORAL	090760-004	Aug 5, 2015		OTC	No	No
Glenmark Pharms Inc	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	TABLET;ORAL	078427-004	Dec 28, 2007		OTC	No	No

Market Dynamics and Financial Trajectory for Cetirizine Hydrochloride

Last updated: February 19, 2026

What Is the Current Market Size and Growth Path?

Cetirizine hydrochloride, a second-generation antihistamine used to treat allergic rhinitis and chronic urticaria, is a mature drug with broad global penetration. The global antihistamine market, valued at approximately $3.2 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 4.6% from 2023 to 2028 [1].

Within this segment, cetirizine's market share dominates, accounting for an estimated 35%, driven by its safety profile and availability in generic forms. Its revenue contribution in this space approximates $1.1 billion annually.

How Do Regulatory and Patent Factors Impact Market Dynamics?

Cetirizine was developed and marketed in the 1980s. Several key patent expirations occurred in the late 2000s, transitioning the drug from patented to generic status. This shift in patent protection led to increased price competition and volume growth.

Generic manufacturers account for roughly 80% of global cetirizine sales, pressuring originator firms to reduce prices. Current patents cover formulations, manufacturing processes, and delivery devices. Most of these patents expired by 2010, with some biosimilar equivalents entering specific markets since 2015.

Potential future patent filings involve novel formulations—such as sustained-release versions or combination products—aimed at differentiating offerings. These might temporarily impact market competition, but existing legal expirations keep price pressure high.

What Are Key Market Drivers and Restraints?

Primary drivers include:

• Rising prevalence of allergies globally, especially in urbanized regions.
• Increasing awareness and availability of over-the-counter (OTC) formulations.
• Expansion into emerging markets with large population bases.

Key restraints involve:

• Market saturation in developed countries.
• Competitive pricing from generic manufacturers.
• The advent of newer antihistamines with improved efficacy or fewer side effects.

How Does Pricing and Revenue Projection Evolve?

Average retail prices for cetirizine in developed markets decline approximately 10-15% annually since patent expiry, driven by generics. The global revenue for cetirizine is projected to stabilize around $1 billion annually over the next 5 years, assuming no significant market disruptions.

Sales volumes are expected to increase modestly, around 3-4% CAGR, mainly attributed to growth in emerging markets like India and Brazil. In these regions, increased healthcare access fuels demand for affordable allergy medications.

What Are Market Trends and Innovation Opportunities?

Despite being a mature drug, opportunities include:

• Development of combination therapies, e.g., cetirizine with decongestants.
• Novel delivery systems, such as sustained-release tablets.
• Focused formulations for children and elderly populations.

However, the core molecule's patent protection remains expired in most markets, limiting exclusivity-driven revenue growth.

What Is the Financial Outlook for Stakeholders?

For pharmaceutical companies:

• Generic firms benefit from high-volume, low-margin sales.
• Innovator companies focus on line extensions or formulations, with limited revenue expansion post-patent expiry.
• R&D investments into new antihistamines or alternative allergy treatments are relatively high compared to returns from cetirizine.

Market players forecast revenue stability, with slight growth prospects limited by generic competition and market saturation.

Summary Table: Key Market Data for Cetirizine Hydrochloride (2023-2028)

Metric	Value	Source
Global antihistamine market	$3.2 billion (2022)	[1]
Cetirizine market share	35% of antihistamine segment	Estimated
Annual revenue (cetirizine)	~$1.1 billion	Estimated
CAGR (2023-2028)	4.6%	[1]
Price decline (since patent expiry)	10-15% annually	Industry reports
Emerging market growth	6-8% CAGR	Market analyses

---

Key Takeaways

• Cetirizine hydrochloride holds a dominant position in the antihistamine market, with stable revenues driven by volume growth in emerging markets.
• Patent expirations have led to increased generic competition, reducing prices and profit margins.
• The market is saturated in developed countries; growth prospects rely on expanding access in emerging economies.
• Innovation focuses on new formulations and combination therapies; core molecule sales remain steady but limited.
• Stakeholders should monitor regulatory changes, biosimilar entries, and formulation innovations for future revenue opportunities.

---

FAQs

1. What factors could disrupt cetirizine's market stability?
Patent challenges, regulatory changes, or the approval of superior allergy medications could impact sales. Additionally, increased self-medication and OTC accessibility could reduce formal market sales.

2. How does cetirizine compare to other antihistamines in efficacy?
Cetirizine has a rapid onset of action and longer duration than first-generation antihistamines. It has a better safety profile than older options but faces competition from newer agents with fewer sedative effects.

3. Are biosimilars influencing cetirizine's market?
Biosimilars are not currently significant for cetirizine as it is a small molecule. However, similar generics or novel formulations could influence sales dynamics akin to biosimilar effects.

4. What regional markets are most promising for growth?
India and Brazil exhibit high growth potential due to increasing healthcare access and population size. Asia-Pacific, in general, is a key region for expansion.

5. How might future formulation innovations impact revenue?
Sustained-release tablets and combination products could command premium pricing, but patent protections are typically limited. The primary impact would be through niche or specialty markets.

---

References

[1] MarketWatch. (2023). Global antihistamine market size, growth, and forecast. MarketWatch.
[2] IQVIA. (2022). Pharmaceutical market analytics report. IQVIA.
[3] Statista. (2022). Over-the-counter allergy medications global sales. Statista.

Note: All projections and data are estimates based on publicly available reports and market analyses as of early 2023.